title: Myocardial stunning following combined modality combretastatin-based chemotherapy: two case reports and review of the literature.
abstract: Myocardial stunning, known as stress cardiomyopathy, broken-heart syndrome, transient left ventricular apical ballooning, and Takotsubo cardiomyopathy, has been reported after many extracardiac stressors, but not following chemotherapy. We report 2 cases with characteristic electrocardiographic and echocardiographic features following combined modality therapy with combretastatin, a vascular-disrupting agent being studied for treatment of anaplastic thyroid cancer. In 1 patient, an ECG performed per protocol 18 hours after drug initiation showed deep, symmetric T-wave inversions in limb leads I and aVL and precordial leads V(2) through V(6). Echocardiography showed mildly reduced overall left ventricular systolic function with akinesis of the entire apex. The patient had mild elevations of troponin I. Coronary angiography revealed no epicardial coronary artery disease. The electrocardiographic and echocardiographic abnormalities resolved after several weeks. The patient remains stable from a cardiovascular standpoint and has not had a recurrence during follow-up. An electrocardiogram performed per protocol in a second patient showed deep, symmetric T-wave inversions throughout the precordial leads and a prolonged QT interval. Echocardiography showed mildly reduced left ventricular function with hypokinesis of the apical-septal wall. Acute coronary syndrome was ruled out, and both the electrocardiographic and echocardiographic changes resolved at follow-up. Although the patient remained pain-free without recurrence of anginal symptoms during long-term follow-up, the patient developed progressive malignancy and died.
authors.affiliation: Harrington-McLaughlin Heart and Vascular Institute, Ireland Cancer Center, and Department of Radiology, University Hospitals-Case Medical Center, Cleveland, Ohio 44106, USA.
authors.forename: Shyam
authors.initials: S
authors.lastname: Bhakta
authors.forename: Susan M
authors.initials: SM
authors.lastname: Flick
authors.forename: Matthey M
authors.initials: MM
authors.lastname: Cooney
authors.forename: John F
authors.initials: JF
authors.lastname: Greskovich
authors.forename: Robert C
authors.initials: RC
authors.lastname: Gilkeson
authors.forename: Scot C
authors.initials: SC
authors.lastname: Remick
authors.forename: Jose
authors.initials: J
authors.lastname: Ortiz
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001632:Bibenzyls / Q000008:administration & dosage / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy; D003952:Diagnostic Imaging; D004562:Electrocardiography; D005260:Female; D006801:Humans; D017682:Myocardial Stunning / Q000139:chemically induced* / Q000175:diagnosis*; D013964:Thyroid Neoplasms / Q000188:drug therapy; D019210:Troponin I / Q000097:blood
chemical_list: D001632:Bibenzyls; D019210:Troponin I; C040105:combretastatin